<DOC>
	<DOCNO>NCT02520284</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability GS-5745 . It consist 3 part : Induction Study ( Cohort 1 ) , Maintenance Study ( Cohort 2 ) , Extended Treatment Phase .</brief_summary>
	<brief_title>Safety Efficacy GS-5745 Adults With Moderately Severely Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Key Ulcerative Colitis ( UC ) confirm endoscopy Moderately severely active UC ( Mayo Score 612 ) May receive oral 5aminosalicylate ( ASA ) , oral corticosteroid , Azathioprine , 6mercaptopurine ( MP ) , methotrexate Treatment failure least one follow agent receive ; Corticosteroids , Immunomodulators , tumor necrosis factoralpha ( TNFÎ± ) Antagonists , Vedolizumab Key Diagnose Crohn 's disease indeterminate colitis Pregnant lactating female Any chronic medical condition ( include , limited cardiac pulmonary disease , alcohol drug abuse ) Exhibit severe UC / clinically significant active infection History malignancy last 5 year Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>